Gil Roth10.08.13
Preclinical
Alnylam advances ALAS-1 attacker . . . read more
Phase I
Acorda begins second HF trial of GGF2 . . . read more
Phase III
Alkermes completes patient enrollment . . . read more
Filings
Cornerstone MDS drug gets orphan status . . . read more
Eleison gets orphan status from EC for osteosarcoma treatment . . . read more
FDA Accepts Keryx NDA for Zerenex . . . read more
Alnylam advances ALAS-1 attacker . . . read more
Phase I
Acorda begins second HF trial of GGF2 . . . read more
Phase III
Alkermes completes patient enrollment . . . read more
Filings
Cornerstone MDS drug gets orphan status . . . read more
Eleison gets orphan status from EC for osteosarcoma treatment . . . read more
FDA Accepts Keryx NDA for Zerenex . . . read more